Pancreatic Cancer Research

ResearcherZhongda Hospital Southeast UniversityActive in the last 2 years

Cailian Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 9 November 2026

Matched on ORCID iD 0000-0002-1728-3137; OpenAlex author ID A5073374316. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. [Expression of Concern] ETS‑1: A potential target of glycolysis for metabolic therapy by regulating glucose metabolism in pancreatic cancer. Last author DOI 10.3892/ijo.2025.5786↗
  2. ETS-1: A potential target of glycolysis for metabolic therapy by regulating glucose metabolism in pancreatic cancer. Last author DOI 10.3892/ijo.2016.3770↗
  3. Transcriptional silencing of ETS-1 abrogates epithelial-mesenchymal transition resulting in reduced motility of pancreatic cancer cells. Co-author DOI 10.3892/or.2014.3613↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhang Xiu · 2 shared papers, 2017–2025 · strength 0.39
  2. Dan Wu · 2 shared papers, 2017–2025 · strength 0.39
  3. Zongdao Rui · 1 shared paper, 2015 · strength 0.05
  4. Chunyan Li · 1 shared paper, 2015 · strength 0.05
  5. Haijun Zhang · 1 shared paper, 2015 · strength 0.05
  6. Min Zhou · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.